The ACME Laboratories Ltd. (DSE: ACMELAB)
Bangladesh
· Delayed Price · Currency is BDT 92.70
+2.10 (2.32%)
At close: Sep 12, 2024
The ACME Laboratories Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | 30,811 | 26,948 | 23,858 | 20,770 | 19,004 | 16,309 | Upgrade
|
| Revenue Growth (YoY) | 19.10% | 12.95% | 14.87% | 9.30% | 16.53% | 10.09% | Upgrade
|
| Cost of Revenue | 18,106 | 16,045 | 14,458 | 12,772 | 11,766 | 9,948 | Upgrade
|
| Gross Profit | 12,706 | 10,902 | 9,401 | 7,998 | 7,237 | 6,361 | Upgrade
|
| Selling, General & Admin | 7,187 | 6,424 | 5,381 | 4,457 | 3,551 | 3,018 | Upgrade
|
| Other Operating Expenses | 3.89 | 3.89 | 3.73 | -96.44 | 5.73 | 5.73 | Upgrade
|
| Operating Expenses | 7,191 | 6,428 | 5,385 | 4,360 | 3,556 | 3,024 | Upgrade
|
| Operating Income | 5,515 | 4,474 | 4,016 | 3,638 | 3,681 | 3,337 | Upgrade
|
| Interest Expense | -2,131 | -1,426 | -1,293 | -1,585 | -1,765 | -1,469 | Upgrade
|
| Interest & Investment Income | 6.99 | 6.99 | 5.73 | 18.01 | 31.96 | 68.92 | Upgrade
|
| Currency Exchange Gain (Loss) | -197.48 | -197.48 | -91.93 | 18.62 | 38.11 | 14.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -210.69 | 32.71 | 55.34 | -16.38 | -9.64 | -4.97 | Upgrade
|
| EBT Excluding Unusual Items | 2,982 | 2,891 | 2,692 | 2,073 | 1,976 | 1,947 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.86 | 3.86 | 1.31 | 0.18 | 3.25 | -3.22 | Upgrade
|
| Asset Writedown | -1.37 | -1.37 | - | - | - | - | Upgrade
|
| Pretax Income | 2,985 | 2,893 | 2,693 | 2,073 | 1,979 | 1,953 | Upgrade
|
| Income Tax Expense | 564.17 | 589.65 | 582.25 | 504.27 | 528.93 | 512.96 | Upgrade
|
| Earnings From Continuing Operations | 2,420 | 2,304 | 2,111 | 1,569 | 1,450 | 1,440 | Upgrade
|
| Net Income | 2,420 | 2,304 | 2,111 | 1,569 | 1,450 | 1,440 | Upgrade
|
| Net Income to Common | 2,420 | 2,304 | 2,111 | 1,569 | 1,450 | 1,440 | Upgrade
|
| Net Income Growth | 9.92% | 9.13% | 34.52% | 8.19% | 0.70% | 0.97% | Upgrade
|
| Shares Outstanding (Basic) | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade
|
| Shares Outstanding (Diluted) | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade
|
| EPS (Basic) | 11.44 | 10.89 | 9.98 | 7.42 | 6.85 | 6.81 | Upgrade
|
| EPS (Diluted) | 11.44 | 10.89 | 9.98 | 7.42 | 6.85 | 6.81 | Upgrade
|
| EPS Growth | 9.92% | 9.13% | 34.52% | 8.26% | 0.63% | 0.99% | Upgrade
|
| Free Cash Flow | -2,885 | -4,001 | -615.35 | 915.26 | -958.2 | -1,867 | Upgrade
|
| Free Cash Flow Per Share | -13.64 | -18.91 | -2.91 | 4.33 | -4.53 | -8.82 | Upgrade
|
| Dividend Per Share | 3.300 | 3.300 | 3.000 | 2.500 | 2.500 | 3.500 | Upgrade
|
| Dividend Growth | 10.00% | 10.00% | 20.00% | 0% | -28.57% | 0% | Upgrade
|
| Gross Margin | 41.24% | 40.46% | 39.40% | 38.51% | 38.08% | 39.00% | Upgrade
|
| Operating Margin | 17.90% | 16.60% | 16.83% | 17.52% | 19.37% | 20.46% | Upgrade
|
| Profit Margin | 7.86% | 8.55% | 8.85% | 7.56% | 7.63% | 8.83% | Upgrade
|
| Free Cash Flow Margin | -9.36% | -14.85% | -2.58% | 4.41% | -5.04% | -11.45% | Upgrade
|
| EBITDA | 7,036 | 5,882 | 5,368 | 4,970 | 4,866 | 4,193 | Upgrade
|
| EBITDA Margin | 22.84% | 21.83% | 22.50% | 23.93% | 25.61% | 25.71% | Upgrade
|
| D&A For EBITDA | 1,522 | 1,407 | 1,352 | 1,332 | 1,185 | 855.78 | Upgrade
|
| EBIT | 5,515 | 4,474 | 4,016 | 3,638 | 3,681 | 3,337 | Upgrade
|
| EBIT Margin | 17.90% | 16.60% | 16.83% | 17.52% | 19.37% | 20.46% | Upgrade
|
| Effective Tax Rate | 18.90% | 20.38% | 21.62% | 24.32% | 26.72% | 26.26% | Upgrade
|
| Advertising Expenses | - | 146.59 | 138.99 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.